Review of NICE Technology Appraisal Guidance No.307; Aflibercept in combination with irinotecan and fluorouracil-based therapy for the treatment of metastatic colorectal cancer which has progressed following prior oxaliplatin-based chemotherapy
Proposal to move the existing guidance to the static list – August 2016
As you may be aware the planned date for review of the above guidance is August 2016.
This is the date at which the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full review appraisal.
No new evidence has been identified that would lead to a change in the existing recommendations.
Consequently we propose that TA307 should move to the ‘static list’ of technology appraisals.
Topics on the static list may be transferred back to the active list for further appraisal if new evidence becomes available that is likely to have a material effect on the last guidance issued.
In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to inform us of any evidence which will help us decide the best way to update this guidance.
Please see appendix A for a full list of the organisations we have contacted.
This page was last updated: